Schisandrin B-mediated TH17 cell differentiation attenuates bowel inflammation

Area of Science:

• Immunology
• Pharmacology
• Traditional Chinese Medicine

Background:

• Schisandrin B (Sch B) is a key component of Schisandra chinensis with known anti-inflammatory properties.
• The precise molecular target and mechanism of action for Sch B's anti-inflammatory effects remain largely undetermined.
• T helper 17 (T_H17) cells play a critical role in the development of autoimmune and inflammatory conditions.

Purpose of the Study:

• To elucidate the molecular target of Schisandrin B (Sch B) responsible for its anti-inflammatory activity.
• To investigate the effect of Sch B on T helper 17 (T_H17) cell function and its therapeutic potential in inflammatory diseases.

Main Methods:

• In vitro studies assessing the impact of Sch B on CD4+ T cell IL-17A production and STAT3 signaling.
• In vivo experiments utilizing mouse models of colitis, including DSS-induced and CD4+CD45RBhigh T cell-induced colitis.

Main Results:

• Schisandrin B was found to inhibit IL-17A production by CD4+ T cells through targeting STAT3 in vitro.
• Sch B demonstrated significant therapeutic efficacy in mouse models of both acute and chronic colitis.
• T_H17 cells were identified as the direct cellular target mediating the anti-inflammatory effects of Sch B.

Conclusions:

• Schisandrin B effectively targets STAT3 in T helper 17 cells, thereby modulating their pro-inflammatory function.
• Sch B exhibits therapeutic potential for treating inflammatory diseases characterized by T_H17 cell hyperactivity.
• Sch B represents a promising lead compound for the development of novel therapeutics against IL-17A-driven inflammatory and autoimmune diseases.